Product Images Pregabalin

This appears to be a calculation formula for predicting creatinine clearance (CLCr) in patients based on their age, weight, and serum creatinine levels. However, it is unclear without further context what the purpose of the CLCr calculation is. Additionally, there may be a typo in the formula where "weignt" is spelled instead of "weight."*

This is a description of Pregabalin capsules, which come in a bottle containing 90 capsules, with the National Drug Code (NDC) number 72205-014-90. The medication is prescription-only and is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ, USA. Each capsule contains 100mg of Pregabalin, and the usual dosage will be prescribed by a doctor; however, the accompanying prescribing information should be consulted for further clarification. The capsules should be stored at a temperature not exceeding 25°C (77°F), with permitted excursions to 15-30°C (59-86°F), and should be held in tight and child-resistant containers. Patients should be given a Medication Guide alongside treatment.*

This is a medication called Pregabalin Capsules with a usual dosage of 150 mg per capsule. It comes in a container with 90 capsules and the National Drug Code (NDC) is 72205-015-90. The manufacturer is MSN Laboratories Private Ltd located in Telangana, India and it is distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. The medication guide should be provided to each patient and the capsules should be stored between 15-30°C (59-86°F) in child-resistant containers. More information can be found at NovadozPharma's website.*

This is a medication guide for Pregabalin Capsules that contain 200mg of pregabalin. It is recommended to be dispensed in tight, child-resistant containers and kept at controlled room temperature. The usual dosage should be determined by consulting the accompanying prescribing information. The medication is distributed by Novadoz Pharmaceuticals and a medication guide should be provided to each patient. It is available only with a prescription. The medication should be stored at 25°C and 77°F with excursions.*

This is a description of Pregabalin Capsules, with a dosage of 225 mg per capsule. It is distributed by Novadoz Pharmaceuticals and comes with a medication guide that should be dispensed to each patient. The usual storage temperature is at 25°C with excursions permitted to 15.30°C. The prescription is only available in light, hid-resistant containers. Manufacturing is done by MSN Laboratories and distributed by Novadoz Pharmaceuticals. The medication guide is available at www.NovadozPharma.com/Products.*

This is information for Pregabalin Capsules, which are available in a 90 capsule bottle containing 25mg of the active ingredient per capsule. The medication should be stored between 15-30°C (59-86°F), and dispensed in a tight, child-resistant container. Further dosing information can be found on the accompanying prescribing information. The medication is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. The medication guide should be provided to each patient.*

This text appears to be a medication label for pregabalin capsules manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC. The usual dosage is not specified, but each capsule contains 300mg of pregabalin. The medication is to be stored at 25°C (77°F) and dispensed in tight, child-resistant containers. The label also includes a product number, manufacturing details, and contact information for Novadoz Pharmaceuticals. The accompanying medication guide is required to be dispensed to each patient.*

This is the description: These are 90 capsules containing pregabalin, each with a dosage of 50 mg. They should be stored at 25°C but can be stored at 15-30°C as permitted by USP controlled room temperature regulations. It is recommended to dispense these capsules in tight, child-resistant containers. The accompanying medication guide should be given to each patient by Novadoz Pharmaceuticals LLC. The product is manufactured by MSN Laboratories Private Limited, Telangana, India. This is an Rx only medication.*

This is a description for Pregabalin Capsules, which are dispensed with an accompanying Medication Guide. The capsules are manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in New Jersey. Each capsule contains 75 mg of pregabalin. The recommended dosage and other important information can be found in the accompanying Prescribing information. The capsules should be stored at room temperature between 15-30°C and in tight, child-resistant containers.*

This is a chart displaying the percent of patients who have shown improvement in pain from baseline after taking different doses of Pregabalin and a placebo. The percent improvement ranges from 0% to 100%.*

This is a graph indicating the percent of patients that improved in pain from baseline when using Pregabalin 100 mg three times a day compared to a placebo. The graph shows the improvement levels ranging from 10 to 100 percent. The cost of treatment is represented by the symbol [$)].*

This is a chart that shows the percentage of patients who improved their pain levels from baseline while taking Pregabalin at different dosages (300mg, 150mg, 75mg) and a placebo. The chart indicates that higher dosages of Pregabalin result in a higher percentage of patients experiencing an improvement in pain. The chart also provides a scale to show percentage improvement from 0 to 100.*

This is a chart showing the percentage of patients who improved while taking different doses of Pregabalin compared to a placebo. The improvement is measured as a percentage reduction in pain from baseline. The chart shows data for pain reductions ranging from more than 10% to more than 90%.*

This text appears to be a chart displaying responder rates for different dosages in a study. The chart shows percentages of responders at different dosage levels and frequencies (BID, TID), and also indicates which responses were statistically significant compared to a placebo group. Study E1 showed a responder rate of 31% at a BID frequency, study E3 showed a responder rate of 43%, and the highest responder rate observed was 51% at a BID frequency. There are also some dosage levels marked with an asterisk indicating that their results were statistically significant compared to placebo.*

This appears to be a graph or chart displaying data for three different "Stukly" products (E1BID, E2BID, E3BID/TID) and a placebo, with the x-axis representing dosage (in mg/day) and the y-axis representing some form of measurement. The chart includes significant p-values for the products compared to the placebo. More context is needed to determine what the measurement and significance of the p-values are.*

This is a graph showing the percent of patients with improved pain levels based on different daily doses of Pregabalin and a placebo, with varying levels of pain improvement indicated on the x-axis. Not available.*

The text indicates a chart or graph that shows the percentage of subjects who improved from baseline to Week 12 when taking Pregabalin medication in comparison to those taking a Placebo medication. The chart shows percentage increments of 10 from 0 to 100. However, without additional context or information, it is not clear what the subjects were being treated for or what "BOCF" stands for.*

The text format appears to be a table representing Percent of Subjects Improved for Pregabalin and Placebo from Baseline to Week 16 BOCF B. The table shows the percentage of subjects who showed improvement in increments of 10%, ranging from 0% to 100%. However, it is not clear what condition or ailment this table refers to, making it difficult to provide a more informative description.*